Full Text View
Tabular View
No Study Results Posted
Related Studies
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
Expanded access is no longer available for this treatment.
Study NCT00636259   Information provided by AstraZeneca
First Received: March 7, 2008   Last Updated: June 10, 2008   History of Changes

March 7, 2008
June 10, 2008
 
 
 
 
Complete list of historical versions of study NCT00636259 on ClinicalTrials.gov Archive Site
 
 
 
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer

This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.

 
 
Expanded Access
 
Adenocarcinoma of the Prostate
Drug: Bicalutamide (Casodex)
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
No longer available
 
 
 

Inclusion Criteria:

  • Patients with adenocarcinoma of the prostate
  • Subjects with locally advanced, and/or metastatic prostate cancer for whom surgical castration or other medical interventions are not considered appropriate or acceptable

Exclusion Criteria:

  • Any known history of abnormal liver function tests
  • Any severe concomitant condition that would make it undesirable, in the clinician's opinion, for the subject to participate in the trial.
  • Known hypersensitivity to bicalutamide or any of the components found in bicalutamide
Male
18 Years and older
 
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00636259
 
7054US/0014, D6874L00006
AstraZeneca
 
 
AstraZeneca
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP